Skip to main content
Fig. 2 | Reproductive Health

Fig. 2

From: Efficacy and safety of a novel pain management device, AT-04, for endometriosis-related pain: study protocol for a phase III randomized controlled trial

Fig. 2

Overview of the study design. After providing consent, eligible women will be randomly assigned to the treatment group, utilizing AT-04, or the control group, utilizing S-02. Participants will use these devices for 16 weeks (double-blind period), after which they will use AT-04 for an additional 4 weeks (actual device usage period)

Back to article page

Reproductive Health

ISSN: 1742-4755